Glembatumumab ELISA Kit
Produktgrößen
96 tests
£1111,00
KDG93101-96TESTS
Über dieses Produkt
- SKU:
- KDG93101
- Zusätzliche Namen:
- CDX-011 (DOX), CR011, glembatumumab vedotin (ADC), CAS: 1020264-78-1
- Anwendung:
- ELISA
- Weitere Details:
- Glembatumumab (CR011) is a fully human IgG2 monoclonal antibody (mAb) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB, or osteoactivin). It was designed to linke to monomethyl auristatin E (MMAE) via a valine-citrulline enzyme-cleavable linker to act as an antibody-drug conjugate (ADC) termed glembatumumab vedotin (also known as CDX-011 and CR011-vcMMAE) for the treatment of advanced, refractory, or resistant GPNMB-expressing breast cancer. It was originally developed through a partnership between CuraGen and Amgen, using Xenomouse technology licensed from Abgenix and ADC technology licensed from Seattle Genetics. Glembatumumab vedotin was in development through April 2018 by Celldex Therapeutics, who acquired CuraGen in 2009. Development of the ADC was discontinued in April 2018 after missing the primary endpoint of its study and failed to help women with tough-to-treat metastatic triple-negative breast cancers (TNBC) stay both alive and progression-free for longer than Roche Holding AG's Xeloda (capecitabine).
- Format:
- Colorimetric
- Immunogen:
- Glembatumumab
- Physischer Zustand:
- Plasma, Serum
- Reichweite:
- 0.31-5 ug/mL
- Empfindlichkeit:
- 0.156 ug/ml
- Versandbedingungen:
- Blue Ice
- Hersteller:
- AntibodySystem
- Typ:
- Assay Kits: ELISAs